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Fractional laser-assisted topical delivery of bleomycin quantified by LC-MS and
visualized by MALDI mass spectrometry imaging
Kristoffer K. Hendela , Charlotte Baggerb, Uffe H. Olesena , Christian Janfeltb , Steen H. Hansenb,
Merete Haedersdala and Catharina M. Lerchea,b
aDepartment of Dermatology, Bispebjerg University Hospital, Copenhagen, Denmark;bDepartment of Pharmacy, University of Copenhagen,
Copenhagen, Denmark
ABSTRACT
Bleomycin exhibits antiproliferative effects desirable for use in dermato-oncology but topical use is
limited by its 1415Da molar mass. Ablative fractional laser (AFL)-assisted drug delivery has been
shown to enhance drug uptake in skin. The aim of this study was with AFL to deliver bleomycin into
skin, quantify uptake, and visualize biodistribution with mass spectrometry. In a Franz diffusion cell
study, pig skin samples (n¼ 66) were treated with AFL (k¼ 10,600nm), 5% density, and 0, 5, 20, or
80mJ/microbeam (mb) pulse energies before exposure to bleomycin for 0.5, 4, or 24h. Bleomycin was
quantified in biopsy cryosections at depths of 100, 500, and 1500mm using high-performance liquid
chromatography-mass spectrometry (LC-MS), and drug biodistribution was visualized for 80mJ/mb
samples by matrix assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI). The
pulse energies 5, 20, and 80mJ/mb resulted in microscopic ablation zones (MAZs) reaching superficial,
mid, and deep dermis respectively. Bleomycin was successfully delivered into the skin and deeper
MAZs and longer exposure time resulted in higher skin concentrations. After 24h, AFL exposure
resulted in significant amounts of bleomycin throughout all skin layers (510mg/cm3, p .002). In
comparison, concentrations in intact skin exposed to bleomycin remained below limit of quantifica-
tion. MALDI-MSI supported the quantitative LC-MS results by visualizing bleomycin biodistribution and
revealing high uptake around MAZs with delivery into surrounding skin tissue. In conclusion, topical
drug delivery of the large and hydrophilic molecule bleomycin is feasible, promising, and should be
explored in an in vivo setting.
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Pretreatment with ablative fractional lasers (AFL) shows
promise to improve topical therapies by enhancing drug
delivery through the skin (Haedersdal et al., 2016). AFL tar-
gets water and in precise microbeams ablates tissue, result-
ing in laser channels termed microscopic ablation zones
(MAZ), with surrounding vertical coagulation zones (CZ) of
variable thickness (Hantash et al., 2007). Drug properties
such as high molecular weight (>500Da) and water solubility
pose challenges to uptake through the lipid bilayers in the
stratum corneum of intact skin (Morrow et al., 2007; Aulton,
2013). AFL-assisted drug delivery has been shown to facili-
tate topical drug uptake of anticancer agents including 5-FU
(130Da) (Wenande et al., 2017), cisplatin (300Da) (Wenande
et al., 2018), vismodegib (431Da) (Olesen et al., 2018), and
methotrexate (455Da) (Taudorf et al., 2015), all of which
have substantially smaller masses than bleomycin (1415Da
and 1426Da for bleomycin A2 and B2, respectively).
Bleomycin is a cytotoxic glycopeptide used in the treat-
ment of a variety of malignant diseases. The drug’s
mechanism of action includes intercalation in DNA and che-
lation with transition metals to induce reactive oxygen spe-
cies (Saitta et al., 2008; Povirk et al., 1979). With chemical
properties including molar masses of 1415–1426Da and a
predicted logP of 7.5 (Kim et al., 2016), bleomycin cannot
cross the skin barrier unassisted to any significant degree.
Bleomycin is approved for systemic use in the treatment
of squamous cell carcinoma, lymphoma, and testicular cancer
(Saitta et al., 2008), and has been used off-label with intrale-
sional administration for a wide variety of malignant and
nonmalignant conditions in dermatology, e.g. basal-cell car-
cinoma (Glass et al., 1997) and keloids (Berman et al., 2017).
AFL-assisted drug delivery of bleomycin may be an alterna-
tive to intravenous and intralesional administration, to enable
a homogenous biodistribution in skin, and minimize sys-
temic effects.
We aim to explore topical delivery of the large and hydro-
philic drug bleomycin after AFL delivery, quantify skin uptake
with high-performance liquid chromatography-mass spec-
trometry (LC-MS), and visualize drug biodistribution in super-
ficial (100 mm), mid (500 mm), and deep (1500 mm) dermis
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Delivery of bleomycin by AFL treatment, reaching three dif-
ferent laser channel depths, was examined in an in vitro
Franz diffusion cell model. Pig skin samples were exposed to
bleomycin for 0.5, 4, or 24 h. A total of eleven interventions
were tested in six repetitions (n¼ 66) including non-AFL
bleomycin interventions and saline controls (Table 1). LC-MS
was used to quantitate bleomycin in cryosections from
superficial, mid, and deep dermis (100, 500, and 1500 mm
depths) along with receiver and donor fluids. MALDI-MSI
imaging visualized cutaneous bleomycin biodistribution (100,
500, and 1500 mm depths) in skin samples treated with the
deepest laser channels.
Skin preparation
Full-thickness skin samples from the flanks of two pigs
(female, 46 and 44 kg) were utilized in the study. Skin was
excised immediately after euthanasia, trimmed for hair, and
relieved of subcutaneous fat. The skin was cut into square
pieces of approximately 3 3 cm, stored for up to a
month at 80 C and thawed to room temperature at
study initiation.
Ablative fractional laser
AFL treatment was performed with a fractional CO2-laser
(10,600 nm, DeepFx handpiece, Lumenis Inc., Santa Clara, CA,
USA). Laser settings comprised single pulses of 5, 20, or
80mJ/microbeam (mb) pulse energy at 5% density, generat-
ing MAZs reaching superficial-, mid- and deep dermis.
Franz diffusion cell model
Immediately after AFL treatment, full-thickness skin samples
were mounted on a Franz cell model (PermeGear Inc.,
Hellertown, PA, USA) consisting of a donor and receiver com-
partment. Skin sample stratum corneum (0.64 cm2) faced
donor compartments, while receiver compartments con-
tained 5.5–5.8ml phosphate buffered saline (pH 7.4, 37 C)
and a magnetic stir bar. At baseline, 750 mL of bleomycin sul-
fate (Baxter, Deerfield, Chicago, USA) (15,000 IU/mL =
7.06mg/mL) was topically applied to skin samples via donor
compartments.
At 0.5, 4, or 24 h diffusion time, skin samples were dis-
mounted, padded dry, and biopsied using an 8-mm punch.
A biopsy from each sample was then mounted on Tissue-Tek
(Sakura, Alphen, Netherlands) for LC-MS quantitation and
laser channel morphology microscopy. The biopsies for
MALDI-MSI were mounted on Milli Q water (ELGA CENTRA-
R200, ELGA LabWater, Buckinghamshire, United Kingdom).
Biopsies were sectioned at skin depths of 100-, 500- and
1500 lm to produce samples of 30 lm thickness for LC-MS
and 10 lm for MALDI-MSI. Samples were stored at 80 C
prior to analysis. For laser channel morphology, cryosections
were stained with hematoxylin-eosin and photo documented
with ProgRes Capture Pro v. 2.8.8 (Jenoptik, Jena, Germany).
Laser channel and coagulation-zone dimensions were digit-
ally measured with ImageJ software v. 1.52c (National
Institute of Health, Maryland, USA).
LC-MS
Before LC-MS quantitation, donor and receiver fluids were
collected directly from the Franz cells. For skin samples, bleo-
mycin was initially extracted from cryosections for 2 h in
1mL PBS, rotating vials every 30min. All samples (250lL)
were then precipitated with 500 mL 2% ZnSO4·7H2O in 25%
methanol, centrifuged at 20,000 rcf for 5min at 4 C and the
supernatant was analyzed by LC-MS. Standards underwent
equivalent analysis.
Quantitative analysis of bleomycin in skin sections, donor,
and receiver compartments was performed using an Agilent
Table 1. Study design overview.
Interventions n MAZa Drug exposure time (hours) Bleomycin Saline MALDI imaginga LC-MSb (n)
1 6 MAZ-Supf 0.5 þ – – 30
2 6 MAZ-Supf 4 þ – – 30
3 6 MAZ-Supf 24 þ – – 30
4 6 MAZ-Mid 0.5 þ – – 30
5 6 MAZ-Mid 4 þ – – 30
6 6 MAZ-Mid 24 þ – – 30
7 6 MAZ-Deep 0.5 þ – þ 30
8 6 MAZ-Deep 4 þ – þ 30
9 6 MAZ-Deep 24 þ – þ 30
10 6 MAZ-Deep 24 – þ þ 30
11 6 No MAZ 24 þ – – 30
Total 66 330
aMatrix assisted laser desorption/ionization (MALDI) imaging was performed on a single sample per intervention.
bCryosections (100, 500, and 1500 mm) were quantified along with the donor and receiver with high-performance liquid chromatography-mass
spectrometry (LC-MS).
MAZ: Microscopic ablation zone.
MAZ-Supf: Microscopic ablation zone reaching superficial dermis.
MAZ-Mid: Microscopic ablation zone reaching mid dermis.
MAZ-Deep: Microscopic ablation zone reaching deep dermis.
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LC system (Agilent Technologies, 1100 series, Santa Clara,
CA, USA) with a binary pump (Agilent 1100 G1312A, Santa
Clara, CA, USA) with a MS Single Quadrupole detector, multi-
mode interface. The LC was equipped with a binary solvent
delivery system and an autosampler. The injection volume
was 10 lL. Separation was achieved at 40 C using a 10-cm
Kinetex XB-C18 column (Phenomenex, Vaerlse, Denmark)
with 1.7 mm particle size and 2.1mm internal diameter.
Bleomycin was analyzed under electrospray ionization in
positive ion mode with detection in selection ion monitoring
mode (SIM) at m/z 707.9 and m/z 713.3. The mobile phases
were (A) 22% acetonitrile in milli Q water þ 0.05% hepta-
fluorobutyric acid and (B) acetonitrile. The gradient started at
0% B at 4min, increased to 90% B at 4–6min, and returned
to 0% B from 6–7min, sustained until 16min. The flow rate
was 0.25ml/min, the spray voltage 4000 V, and the drying
gas flow rate 9 L/min. The limit of quantification (LOQ) was
75 ng/ml.
Units and calculations
Skin bleomycin concentrations (mg/cm3 and IU/cm3) were
calculated based on cryosection dimensions of a halved
biopsy with a surface area of 0.25 cm2 and thickness of
0.003 cm. Receiver concentrations (mg/cm2) were calculated
based on the exposed skin area of the Franz cell setup
(0.64 cm2). Percentage of applied concentration present in a
cryosection was based on the donor chamber concentration
of bleomycin (7.06mg/mL). In the result section, all concen-
trations mentioned are median values of 6 repetitions and p-
values represent the difference between the intervention
and control (non-AFL bleomycin treated skin for 24 h).
Bleomycin imaging in skin
Qualitative determination of the distribution of bleomycin
was performed on a Thermo QExactive Orbitrap mass spec-
trometer equipped with an AP-SMALDI-10 ion source
(TransMIT, Giessen, Germany). MALDI imaging was performed
on 12 samples and 4 control tissue sections. Prior to analysis,
10 mm sections of frozen tissue, both horizontal at 100, 500
and 1500mm depth and selected vertical sections, were
thawed in a vacuum desiccator and spray-coated with a
30mg/mL solution of 2,5-dihydroxybenzoic acid in 50:50
methanol/water with 1% trifluoroacetic acid (Hsieh et al.,
2007). 300 mL of matrix solution was pneumatically sprayed
at a pressure of 2.5 bar, a flow rate of 30 mL/min and a dis-
tance between the sample and spray tip of 110mm to form
a homogenous layer of matrix crystals covering an area of
approximately 18mm in diameter. While applying the matrix
solution, the sample was rotated at 600 rpm. The mass spec-
trometer was operated in positive ion mode (scan range m/z
400–1600) at mass resolving power of 14,0000@m/z 200. A
mass accuracy of 1 ppm was ensured by using a matrix peak
as lock-mass. The samples were imaged with pixel sizes of
40 mm for horizontal tissue sections and 35 mm for vertical tis-
sue sections. The control tissue sections were analyzed using
a pixel size from 100–120 mm, depending on the size of the
section. Raw data was converted to imzML (Imaging mass
spectrometry markup language) using an imzML converter
(Schramm et al., 2012). Images were generated in MSiReader
0.06 using a bin width of 0.02Da (Robichaud et al., 2013).
The image analysis was performed using accurate masses of
the two forms of bleomycin in positive ion mode (m/z
1415.52609 and 1425.56323) and the tissue was localized on
basis of the localization of the endogenous phospholipid
PC(34:1) (m/z 798.54092).
Figure 1. Laser channel morphology and dimensions in HE-stained cryosections. (A) MAZ-Supf, depth: 195 mm (158–219 mm), width: 89 mm (80–101 mm), and
coagulation zone: 34 mm (28–35 mm), n¼ 17 channels. (B) MAZ-Mid, depth: 602 mm (513–665 mm), width: 140 mm (118–160 mm), and coagulation zone: 47 mm
(43–51 mm), n¼ 21 channels. (C) MAZ-Deep, depth: 1496 mm (1324–1599 mm), width: 251 mm (197–286 mm), and coagulation zone: 65 mm (60–76 mm), n¼ 21
channels. The coagulation-zones bordering the laser channels are visualized by more intense hematoxylin staining than the surrounding tissue. Dimensions are
shown as median with interquartile range. Magnification 40. MAZ-Supf: Microscopic ablation zone reaching superficial dermis; MAZ-Mid: Microscopic ablation
zone reaching mid dermis; MAZ-Deep: Microscopic ablation zone reaching deep dermis.
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2,5-dihydroxybenzoic acid and trifluoroacetic acid were
purchased from Sigma-Aldrich. Methanol was from
ChemSolute/TH Geyer. Milli Q water was produced on a
Millipore Direct-Q3 (Merck, Darmstadt, Germany).
Statistical analyses
Descriptive statistics are presented as medians with interquartile
ranges. Testing for statistical significance (5% level), unpaired
samples were compared using the non-parametric
Kruskal–Wallis and Mann–Whitney U tests. If concentrations
were below LOQ (75ng/ml) the LOQ value was used in the cal-
culations. All p-values are exact values and two-tailed. Statistical
tests were computed in SPSS 24 (IBM Corporation, Armonk, NY,
USA). Graphical presentation of data was plotted using
GraphPad Prism 7 (GraphPad Software Inc., San Diego, CA, USA).
Results
Laser channel dimensions
Pulse energies of 5, 20 and 80mJ/microbeam resulted in
median MAZs reaching the superficial- (MAZ-Supf; 195 lm
depth), mid- (MAZ-Mid; 602 lm depth) and deep dermis
(MAZ-Deep; 1496 lm depth). Histological evaluations of
MAZs are shown in Figure 1.
LC-MS quantified bleomycin concentrations
Overall, drug uptake depended on MAZ depth and exposure
time, resulting in higher bleomycin concentrations using deeper
MAZs and longer exposure times (Figure 2 and Table 2).
After 24 h of drug exposure, all three MAZs depths pro-
vided significantly increased bleomycin concentrations in all
skin layers (p .002). Thus, MAZ-Supf, MAZ-Mid and MAZ-
Deep delivered concentrations of 722, 1107, and 1658 mg/
cm3 bleomycin in superficial dermis, 670, 1104, and 1918 mg/
cm3 in mid dermis, and 510, 680, and 1100mg/cm3 bleo-
mycin in deep dermis, respectively (Table 2 and Figure 2(C)).
In non-AFL-exposed skin, bleomycin concentrations remained
below LOQ in all skin layers.
At shorter exposure times, MAZs similarly facilitated signifi-
cant concentrations of bleomycin in the superficial and mid
dermis, though not all MAZ depths resulting in bleomycin in
the deep dermis. After 0.5 h of drug exposure, bleomycin
reached the superficial dermis with MAZ-Supf (109mg/cm3,
p=n.s.), MAZ-Mid (204mg/cm3, p¼ .026) and MAZ-Deep
(302mg/cm3, p¼ .002). As seen in Table 2 and Figure 2(A),
after short-term 0.5 h of drug exposure, only MAZ-Deep deliv-
ered bleomycin into mid dermis (150mg/cm3, p¼ .041), and
none of the MAZ depths facilitated delivery into deep dermis
After 4 h of topical drug exposure, further increases in
bleomycin were observed in the superficial dermis with
MAZ-Supf (287mg/cm3, p¼ .004), MAZ-Mid (484mg/cm3,
p¼ .002) and MAZ-Deep (695 mg/cm3, p¼ .002). Bleomycin
was also detected in the mid dermis with MAZ-Supf (211 mg/
cm3, p¼ .041), MAZ-Mid (434 mg/cm3, p¼ .002) and MAZ-
Deep (547 mg/cm3, p¼ .026). In deep dermis, MAZ-Mid and
MAZ-Deep delivered 163 mg/cm3 (p¼ .015) and 183 mg/cm3
(p¼ .093) bleomycin, respectively (Table 2 and Figure 2(B)),
while MAZ-Supf delivery was below LOQ (data not shown).
Bleomycin concentrations in the transdermal receiver
chambers were below LOQ or negligible after 0.5 and 4 h of
drug exposure with all MAZs. After 24 h, bleomycin reached
quantifiable concentrations (Table 2). For all interventions,
donor compartments contained more than 75% of the ori-
ginally applied bleomycin concentration at examined time
points (data not shown). Normal saline controls were nega-
tive for bleomycin by LC-MS analysis.
Figure 2. Bleomycin concentrations by exposure time, pulse energies, and skin
depth. Boxplots of quantified bleomycin based on median and interquartile
range with min/max whiskers for (A) 0.5 h, (B) 4 h, and (C) 24 h drug exposure
time. Higher concentrations of bleomycin are seen closer to the skin surface.
Higher pulse energies and longer drug exposure times result in higher concen-
trations of bleomycin. The y-axes are not standardized between diagrams.
The dotted lines represent the limit of quantification. MAZ-Supf: Microscopic
ablation zone reaching superficial dermis; MAZ-Mid: Microscopic ablation zone




In Figure 3, enhancement ratios depending on MAZ depth and
exposure time are shown as a heatmap of investigated skin
layers. As illustrated, skin pretreatment with AFL
enabled topical delivery of bleomycin with deeper MAZs result-
ing in enhanced delivery. Longer drug exposure times further
enhanced concentrations. Four hours drug exposure time using
MAZ-Deep thus offered the same enhancement ratio in super-
ficial skin as 24h exposure with MAZ-Supf.
MALDI mass spectrometry imaging
Qualitative imaging revealed bleomycin concentrating primarily
in CZs, though also present in surrounding tissue (Figure 4(A)).
Supporting quantitative LC-MS data, a trend of higher concen-
trations with increased drug exposure time was seen. The high-
est concentrations of bleomycin were noted in the superficial
dermis, with decreasing intensity down through the skin layers.
Drug imaging of the superficial dermis (Figure 4(Ba–Bc))
indicated increasing concentrations of bleomycin over time.
Table 2. Quantification and comparison of bleomycin in intervention and control skin.
Intervention n Sample
Quantified bleomycin concentration (median)
Percentage of applied conc. Compared with controlLC-MSa per cm3 skinb Receiverc
ng/mL (IQR) lg/cm3 IU/cm3 lg/cm2 % p-value
No MAZ
24 h 6 100 mm LOQ (LOQ–114.0) – – – Control
500 mm LOQ (LOQ–101.0) – – – Control
1500 mm LOQ (LOQ) – – – Control
Receiver LOQ (LOQ–85.0) –
MAZ-Supf
0.5 h 6 100 mm 82.0 (LOQ–101.0) 109 232 1.6 .818
500 mm LOQ (LOQ) – – – –
1500 mm LOQ (LOQ) – – – –
Receiver LOQ (LOQ) –
4 h 6 100 mm 215.5 (176.0–234.0) 287 610 4.1 .004
500 mm 158.5 (151.0–164.0) 211 449 3.0 .041
1500 mm LOQ (LOQ) – – – –
Receiver LOQ (LOQ) –
24 h 6 100 mm 541.5 (537.0–545.0) 722 1533 10.2 .002
500 mm 503.0 (438.0–604.0) 671 1424 9.5 .002
1500 mm 382.5 (254.0–427.0) 510 1083 7.2 .002
Receiver 888.5 (714.0–972.0) 7.8
MAZ-Mid
0.5 h 6 100 mm 153.0 (148.0–173.0) 204 433 3.0 .026
500 mm LOQ (LOQ –114.0) – – – –
1500 mm LOQ (LOQ) – – – –
Receiver LOQ (LOQ) –
4 h 6 100 mm 363.5 (281.0–424.0) 489 1029 6.9 .002
500 mm 325.5 (303.0–355.0) 434 922 6.1 .002
1500 mm 122.50 (97.0–167.0) 163 347 2.3 .015
Receiver LOQ (LOQ) –
24 h 6 100 mm 830.5 (759.0–924.0) 1107 2352 15.7 .002
500 mm 828.0 (702.0–933.0) 1104 2345 15.6 .002
1500 mm 510.5 (402.0–582.0) 681 1446 9.6 .002
Receiver 1317.5 (441.0–2001.0) 11.5
MAZ-Deep
0.5 h 6 100 mm 227.0 (215.0–261.0) 303 643 4.3 .002
500 mm 112.5 (104.0–185.0) 150 319 2.1 .041
1500 mm LOQ (LOQ) – – – –
Receiver LOQ (LOQ) –
4 h 6 100 mm 521.0 (476.0–621.0) 695 1427 9.8 .002
500 mm 410.0 (309.0–552.0) 547 1161 7.7 .026
1500 mm 137.5 (LOQ–196.0) 183 389 2.6 .093
Receiver LOQ (LOQ) –
24 h 6 100 mm 1244.0 (1010.0–1400.0) 1659 3522 23.5 .002
500 mm 1438.5 (1035.0–1635.0) 1918 4073 27.2 .002
1500 mm 825.0 (676.0–883.0) 1100 2336 15.6 .002
Receiver 4380.5 (3775.0–5178.0) 38.3
MAZ: Microscopic ablation zone.
MAZ-Supf: Microscopic ablation zone reaching superficial dermis.
MAZ-Mid: Microscopic ablation zone reaching mid dermis.
MAZ-Deep: Microscopic ablation zone reaching deep.
LOQ: Below limit of quantification (75 ng/mL).
IQR: Interquartile range (Q1-Q3).
aConcentration as measured with LC-MS.
bCryosection volume is 0.00075 cm3 (surface area 0.25 cm2  thickness 0.003 cm).
cSurface area is 0.64 cm2.
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Despite poorly defined cryosection outlines, imaging also
revealed visible laser channels in analyzed samples.
Mid dermis imaging (Figure 4(Bd–Bf)) showed well-defined
skin sample outlines with an organized grid of MAZs. Peak
bleomycin concentrations were detected corresponding to
CZs and a trend for higher concentrations is seen with
increasing drug exposure time.
Deep dermis imaging (Figure 4(Bg–Bi)) showed no visible
bleomycin in the center of the 0.5-hour image but the drug
is present peripherally (Figure 4(Bg)). This corresponds to the
quantitative analysis by LC-MS being below LOQ. The 4 and
24 h images (Figure 4(Bh,Bi)) show well-defined outlines and
grid-organized laser channels with a trend of higher bleo-
mycin concentrations with increasing drug exposure time.
No bleomycin was detected in negative control samples
with normal saline (data not shown).
Discussion
The present study is the first assessment of AFL-assisted topical
delivery of bleomycin quantified with LC-MS and visualized with
MALDI-MSI. Bleomycin was successfully delivered into the deep
dermis by AFL while drug detection in non-AFL exposed skin
was negligible even at superficial depths (Table 2 and Figure
2(C)). Bleomycin concentrations depended on MAZ depth, and
higher concentrations of drug in tissue were achieved using
deeper MAZs and longer drug exposure times. As expected, a
non-linear relationship between drug uptake and MAZ depth as
well as exposure time was observed, indicating a saturation level
of bleomycin in the skin similar to data published for other
drugs previously delivered by AFL in vitro, e.g. 5-FU (Wenande
et al., 2017) and methotrexate (Taudorf et al., 2015).
The quantitative LC-MS results are supported by the quali-
tative MALDI-MSI. Furthermore, the qualitative imaging data
provided insight in biodistribution and confirms high uptake
of bleomycin in CZs as well as substantial delivery in the sur-
rounding skin tissue. It has been hypothesized that AFL-
induced CZs function as a barrier against drug uptake
(Erlendsson et al., 2016). However, in the present study, we
utilized MALDI imaging to demonstrate substantial
biodistribution beyond CZs, similar to what has previously
been shown with smaller drugs than bleomycin, e.g. 5-FU
(Wenande et al., 2017). Thus, our data is in line with previous
research which shows high uptake in CZs with other topic-
ally-applied compounds (Haak et al., 2017).
AFL-assisted delivery of bleomycin appears to be a prom-
ising candidate for a new topical treatment with uniform
and reproducible biodistribution. The AFL modality is associ-
ated with less interphysician variance than might be
expected with current local treatment methods, e.g. injection
delivery. AFL-assisted drug delivery may also enable precision
delivery to specific skin depths and might also limit transder-
mal access to the vascular system and systemic effects; an
advantage of local therapy. Although cutaneous biodistribu-
tion is highly dependent on drug concentrations and charac-
teristics, a recent in vivo study investigating AFL-assisted
cisplatin (300Da) and 5-FU (130Da) delivery did not find any
quantifiable transdermal uptake (Wenande et al., 2018),
which indicates that systemic access might be limited
depending on the drug and treated area.
AFL-assisted drug delivery in a clinical setting can reduce
the need for long drug exposure times. After just 30min,
deep laser channels yielded almost the same drug uptake
enhancement ratio in superficial skin as superficial channels
after 4 h drug exposure. Thus, increasing MAZ-depth may
dramatically reduce drug exposure time.
Compared with reported IC50 test results, our data suggests
that AFL-assisted drug delivery of bleomycin can provide clinic-
ally relevant concentrations with all tested MAZs. Two studies
listed in the Genomics in Drug Sensitivity Cancer (GDSC) pro-
ject database differ greatly in their IC50 test results for bleo-
mycin on a wide range of cell lines. For the often-used SCC-25
cell line, reported values were 0.97mg/cm3 (0.69mM) and
219mg/cm3 (155mM), respectively (Yang et al., 2012).
Another study on the same cell line suggests 15.0mg/cm3
(10.7 mM) after 24 h (Olesen et al., 2017a). Importantly, all
three values can easily be reached using AFL under in
vitro conditions.
We used the standard vehicle for bleomycin for our Franz
diffusion cell study, an aqueous saline solution. Topical appli-
cation in the clinic may benefit from a more viscous
Figure 3. Heatmap of enhancement ratios. Bleomycin concentration enhancement ratios achieved by increasing MAZ depth energy and/or extending the drug
exposure time for the superficial, mid, and deep dermis, respectively. For each skin depth separately, the smallest MAZ and drug exposure time setting resulting in
a median concentration above the limit of quantification (LOQ) is normalized to 1.00 as a base for enhancement ratios. Thus, values are normalized to Superficial
dermis: 82 mg/cm3 (MAZ-Supf and 0.5 h), Mid dermis: 112.5 mg/cm3 (MAZ-Deep and 0.5 h), Deep dermis: 122.5 mg/cm3 (MAZ-Mid and 4 h). A darker hue of blue sig-
nifies a higher enhancement ratio. Crossed out cells signify values below LOQ. MAZ-Supf: Microscopic ablation zone reaching superficial dermis; MAZ-Mid:
Microscopic ablation zone reaching mid dermis; MAZ-Deep: Microscopic ablation zone reaching deep dermis.
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formulation in order to adhere securely on the skin for the
duration of the treatment, e.g. a gel-based vehicle. In a recent
study, we compared different types of vehicles for use with
laser-assisted delivery and found that a gel-based vehicle
enters the skin almost as effectively as a liquid solution
(Olesen et al., 2017b). Future in vivo studies might investigate
bleomycin’s efficacy and compatibility with different vehicles
compared with normal saline. Other factors including drug
loading in skin (Karadzovska et al., 2012), closing of laser chan-
nels over time (Banzhaf et al., 2017), and vascular wash-out
effects also represent areas of further investigation, though
best studied in vivo (Oni et al., 2012; Ibrahim et al., 2018).
A limitation of this in vitro study represents the almost infin-
ite supply of bleomycin dissolved in normal saline available to
the skin during exposure. This does not necessarily translate to
clinical settings, but may emulate continuous application under
Figure 4. Mass spectrometry imaging. MALDI-MSI of bleomycin B2 (m/z 1425.56323) with MAZ-Deep laser channels. (A) Vertically cut skin cryosection after 24 h of
topical drug exposure. Laser channels are easily seen with high concentrations of bleomycin (yellow) in the coagulation zones and drug dissemination into the sur-
rounding tissue. (B) Horizontally cut skin cryosections. A trend towards higher concentrations is seen along the x-axis of time, and lower down the y-axis of skin
depth. The depicted intensity values for each image are based on maximum bleomycin detection within the individual skin sample and thus cannot be compared
inter-individually. MALDI-MSI: Matrix assisted laser desorption/ionization mass spectrometry imaging; MAZ-Deep: Microscopic ablation zone reaching deep dermis.
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occlusion during a similar time-frame in the clinic. Furthermore,
Figures 4(Bg–Bi) suggest that punch biopsy can cause depres-
sion of peripheral tissue from the skin surface downwards,
resulting in cryosections from deep skin compartments display-
ing tissue from more superficial layers in their outer rims.
Higher drug concentrations would in consequence be visualized
in the periphery of the cryosections, a phenomenon similarly
observable in earlier studies (Wenande et al., 2017). Finally, a
few samples of non-AFL-exposed skin were shown to contain
bleomycin. However, this finding most likely reflects inadvertent
contamination during handling and these low concentrations
near the LOQ had a limited impact on our findings.
In conclusion, we show for the first time that AFL-assisted
topical drug delivery of the large hydrophilic molecule bleo-
mycin is feasible. Cutaneous bleomycin concentrations can be
increased by using deeper MAZs and longer exposure times.
Imaging further reflected the quantitative LC-MS data by visu-
alizing bleomycin distributed in CZs and surrounding tissue, as
well as higher drug concentrations associated with increased
exposure time. AFL-assisted bleomycin delivery appears to be
a promising candidate for future in vivo studies.
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